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A B S T R A C T
A nationwide laboratory-based surveillance system for invasive group A streptococcal (GAS) infections
was conducted in The Netherlands from March 1992 until December 2003. Until 1996, all isolates
submitted were evaluated clinically and demographically. During this period there was a transition
from passive to active surveillance for some of the participating laboratories, corresponding to a
national coverage of 50%. During active surveillance, participating laboratories submitted twice as
many isolates from invasive GAS disease, whereas the relative submission of isolates representing very
severe manifestations (toxic shock-like syndrome, fatality) did not increase. From 1997 onwards,
invasiveness was defined solely on the basis of source of isolation (without clinical evaluation). During
the period of microbiological and clinical evaluation, microbiological evaluation alone was found to be
specific (> 99%), but had limited sensitivity (66%). Estimation of the true rate of invasive GAS disease
should be based on an active surveillance system with inclusion of both microbiological and clinical
data.
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I N T R O D U C T I O N
After a steady decrease in morbidity and mortal-
ity resulting from severe group A streptococcal
(GAS) infections, the last two decades have
witnessed a resurgence of invasive GAS disease,
and a number of prospective and population-
based studies have reported rates of incidence
and mortality. Some of these studies have relied
on both clinical and microbiological findings for
their definition of invasive GAS disease [1–6].
According to the Working Group on Severe
Streptococcal Infections, invasive GAS disease
consists of ‘definite’ and ‘probable’ cases [7].
Definite invasive GAS disease is defined as the
isolation of group A streptococci from a normally
sterile site in conjunction with clinical symptoms
of invasive bacterial disease. Isolation of group A
streptococci from a normally non-sterile site in
association with invasive bacterial disease is
defined as probable invasive GAS disease. Since
the isolation of group A streptococci from a
normally sterile body site constitutes invasive
GAS disease, other studies have relied only on
microbiological data, including isolates obtained
from normally sterile sources such as blood,
biopsy material, cerebrospinal fluid and synovial
fluid [8–12]. For some population-based studies, it
remains unclear whether surveillance was active
or passive, which potentially affects the efficiency
of reporting [13]. In the present study, the effect of
actively stimulating a GAS surveillance system
was evaluated. Also, the additional value of
integrating clinical data in this surveillance sys-
tem, together with the implications for incidence
calculations, was assessed. This report focuses on
these epidemiological considerations. Clinical and
demographic features of invasive GAS disease in
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The Netherlands, as determined from this study,
have been published previously [14–17].
M A T E R I A L S A N D M E T H O D S
Surveillance of invasive GAS disease
Nationwide laboratory-based surveillance for invasive GAS
infections was conducted at the National Institute of Public
Health (RIVM), Bilthoven, from March 1992 until December
2003 (average population during this period: 15 655 447)
[14–17]. Initially, all Dutch clinical microbiology laboratories,
comprising Regional Public Health Laboratories (RPHLs) and
other laboratories, participated in this surveillance system on a
voluntary basis. GAS isolates, known or suspected to be
associated with invasive disease, were sent to the RIVM,
together with information regarding patient age, gender and
source of isolation. From March 1992 to December 1996, a
questionnaire was returned to the medical microbiologist and
treating physician to obtain clinical and demographic data for
the patients involved. Invasive streptococcal disease was
defined as the isolation of Streptococcus pyogenes froma normally
sterile body site (definite invasive GAS disease), or from a
normally non-sterile body site in conjunction with clinical
symptoms consistent with invasive GAS disease (probable
invasive GAS disease) [7]. From May 1994, the surveillance
system was organised formally for RPHLs (estimated national
coverage of 50%), including reimbursement of costs for every
invasiveGAS isolate submitted. RPHLswere required to submit
weekly reports on the number or absence of GAS isolates
obtained from normally sterile sites. This active surveillance
system with RPHLs continued until December 2003. In Decem-
ber 1996, GAS surveillance was continuedwith RPHLs only (no
other laboratories were involved), and clinical evaluation of
reported and submitted isolates was discontinued.
Descriptive epidemiology
To evaluate the effect of switching to active surveillance,
relative increases or decreases in the numbers of isolates
submitted by RPHLs after May 1994 were compared to data
from RPHLs before May 1994, and from other laboratories
before and after May 1994 as a reference. The sensitivity and
specificity of microbiologically defined invasiveness were
calculated with respect to the standard of both microbiological
and clinical evaluation (1992–1996). After December 1996,
when clinical evaluation ceased, this sensitivity figure was
used to estimate the annual incidence of invasive GAS disease
from RPHL data.
Laboratory methods
Identification of isolates was confirmed using bacitracin
susceptibility testing and latex agglutination tests (Streptex;
Wellcome, Dartford, UK). All isolates were M-genotyped by
hybridisation of the denatured emm-amplicon with a panel of
26 emm-type specific probes in a reverse line blotting system
[18].
Statistics
Differences in group proportions were assessed by the chi-
square test.
R E S U L T S
During the surveillance period with clinical eval-
uation (March 1992 to December 1996), RPHLs
and other laboratories submitted 2437 GAS iso-
lates to the RIVM (Fig. 1). A complete question-
naire with demographic and clinical data was
obtained for 1312 (54%) of 2437 patients. All
isolates were M-genotyped, and the age and
gender of most patients (98% and 86%, respect-
ively) were known. The data summarised in
Table 1 show that there were no significant
differences in patient (age distribution and gen-
der) and isolate (M-type distribution) character-
istics between the response and non-response
groups.
During the period of passive surveillance
(March 1992 to May 1994), RPHLs and other
laboratories submitted similar numbers of isolates
from clinically invasive GAS disease (RPHLs, 77
definite and 35 probable cases; other laboratories,
66 definite and 42 probable cases; Fig. 1). This
confirmed that the national coverage of RPHLs
for invasive GAS disease was c. 50%. Thus,
incidence estimates for invasive GAS disease
were the same as calculated from RPHLs and
other laboratories in the period before May 1994.
Furthermore, trends in time, estimated mortality
and the relative contribution of predominant
M-types were very similar (data not shown).
As the surveillance system was not altered for
the non-RPHL laboratories, their data served as a
reference denominator for evaluating the effects
of the switch to active surveillance for RPHLs
after May 1994 (Table 2). After May 1994, RPHLs
submitted significantly more isolates, both micro-
biologically invasive as well as microbiologically
non-invasive or unknown (Fig. 1 and Table 2).
With integration of clinical data, the submission
from RPHLs of isolates representing invasive
(probable and definite) GAS disease increased
two-fold, but submission of isolates associated
with severe manifestations of invasive GAS dis-
ease, as measured by toxic shock-like syndrome
(TSS) and fatality, did not increase (Table 2).
Following assessment of clinical and microbio-
logical data, 880 of 1312 cases evaluated were
characterised as either definite (n = 582) or prob-
ably invasive (n = 298) GAS disease (Fig. 1). Of
these evaluated cases, 585 isolates were consid-
ered to represent definite invasive GAS disease
based on microbiological criteria alone (Fig. 1).
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Three (< 1%) of these isolates were clinically non-
invasive when the clinical evaluation was taken
into account. When compared to the reference
standard of clinical and microbiological data
(Table 3), defining invasive GAS disease solely
on the basis of the source of the isolate had a
specificity for the presence of clinically invasive
disease of 99% (429 ⁄ 432) and a sensitivity of 66%
(582 ⁄ 880).
Since almost 100% specificity was obtained for
defining invasive GAS disease on the basis of
microbiological criteria alone, active surveillance
was continued with RPHLs without clinical eval-
uation from January 1997 to January 2004. During
these 8 years, GAS isolates obtained from nor-
mally sterile body sites of 1009 patients were
submitted by RPHLs. The limited sensitivity as a
result of not including clinical evaluation, as
calculated from the period 1992–1996, was taken
into account for annual incidence calculations.
The incidence of invasive GAS disease was at its
lowest in 1999, but then increased to levels similar
to those observed in the mid-1990s [19].
2437
1289226579343
189 
(55%)
135 
(60%)
676 
(52%)
312 
(54%)
281 
(42%)
66 
(35%)
123 
(65%)
160 
(51%)
152 
(49%)
78 
(58%)
57 
(42%)
395 
(58%)
66 
(100%)
42 
(34%)
159 
(99%)
61 
(40%)
77 
(99%)
35 
(61%)
160 
(41%)
280 
(100%)
23 
(35%)
9    
(21%)
49 
(31%)
13 
(21%)
31 
(40%)
8   
(23%)
71 
(25%)
11   
(7%)
Other labs 3/1992-4/1994 Other labs 5/1994-12/1996 RPHLs 3/1992-4/1994 RPHLs 5/1994-12/1996
Clinically evaluated 
(n=1312)
Microbiologically invasive 
(n=585)
Microbiologically non-invasive/ 
unknown (n=727)
Clinically invasive 
(n=880)
TSS 
(n=215)
Fig. 1. Numbers of group A streptococcal (GAS) isolates submitted by Regional Public Health Laboratories (RPHLs) and
other laboratories in March 1992 – April 1994 and May 1994 – December 1996. Cases of definite invasive GAS disease are
shown in solid squares. Cases of probable invasive GAS disease are shown in dashed squares. TSS, toxic shock-like
syndrome.
Table 1. Evaluation of potential reporting bias of group A
streptococci by comparison of patient (age and gender)
and microbial (M-genotype) characteristics between the
response and non-response groups
Response (n = 1312) Non-response (n = 1125)
Median age (quartiles; years) 34 (18–53) 36 (20–58)
Male:female ratio 0.9:1.0 0.8:1.0
M-type
1 246 (19%) 216 (19%)
3 122 (9%) 104 (9%)
28 112 (9%) 77 (7%)
6 74 (6%) 71 (6%)
12 72 (5%) 49 (4%)
89 63 (5%) 85 (8%)
Other 623 (47%) 523 (46%)
Table 2. Relative change in numbers of group A strepto-
coccal isolates submitted by Regional Public Health Labor-
atories (RPHLs) after May 1994, using data from other
laboratories before and after May 1994 and RPHLs before
May 1994 as a reference denominator
Change in no.
of isolates
All isolates 3.4a
Microbiologically defined
Invasive 1.5b
Non-invasive ⁄unknown 5.6a
Clinically defined
Invasive (probable + definite) 2.0a
Non-invasive 9.0a
TSS 1.1
Mortality 0.82
ap < 0.0001 in comparison to period March 1992 to May 1994.
bp < 0.05 in comparison to period March 1992 to May 1994.
TSS, toxic shock-like syndrome.
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D I S C U S S I O N
In response to reports of a worldwide increase in
the incidence of severe invasive GAS infections, a
surveillance system that relied on the voluntary
cooperation of microbiological laboratories was
initiated in The Netherlands in 1992. However,
from May 1994, RPHLs were required to report
weekly on the number of invasive GAS isolates,
with financial compensation for each isolate repor-
ted and submitted. During the first 2 years of
passive notification, both RPHLs and other labor-
atories generated very similar epidemiological
data. Thus, the unaltered passive surveillance
system for non-RPHL laboratories, which contin-
ued until December 1996, was a valid reference
denominator againstwhich to evaluate the effect of
a transition from a passive to an active surveillance
system on different epidemiological parameters.
After the initiation of active surveillance, the
estimated incidence of all invasive GAS infections
based on RPHL data increased two-fold. Similarly,
reports of GAS bacteraemias more than doubled
between 2002 and 2003 in England, Wales and
Northern Ireland as a result of the enhanced Strep-
EURO surveillance scheme that was initiated in
January 2003 [20]. It was noted that, despite the
overall increase in estimated incidence, the num-
ber of fatal cases or cases involving TSS notified by
RPHLs did not increase after the institution of
active surveillance. Thus, in a system involving
passive notification, very severe cases appear to be
detected almost as well as in a system of active
stimulation. Possibly because of their severe
effects, there appears to be high compliance in
submitting these isolates, irrespective of the nature
of the surveillance system.
The clinical symptoms of severe invasive GAS
disease in The Netherlands during 1992–1996
have been reported previously [17]. Few cases of
severe invasive GAS disease appear to have been
missed during this period. However, an actively
stimulated surveillance system is much more
sensitive for ‘milder’ (i.e., non-fatal and non-
TSS) cases of invasive GAS disease, and can
therefore be expected to give a more accurate
estimate of the incidence of all cases of invasive
GAS disease. Interestingly, the relative contribu-
tion of TSS to all cases of invasive GAS disease
has been reported to be higher in a passive
surveillance study compared to active surveil-
lance studies; thus, Svensson et al. [5] reported
TSS in 24% of all cases, whereas active popula-
tion-based studies reported TSS in 13% and 6% of
cases, respectively [1,4]. However, these reported
differences may be the result of different study
designs rather than geographical variations.
An accurate estimate of the incidence of inva-
sive GAS disease must also rely on clinical
evaluation (including the use of questionnaires)
to detect probable cases. No active follow-up of
questionnaires was undertaken, and thus report-
ing bias might have been introduced. The overall
response rate in the present study was 54%,
similar to other reports regarding nationwide
surveillance studies of bacterial infectious diseases
[21,22]. Since age and gender of the patient were
registered routinely following submission of an
isolate, these data were known for both evaluated
and non-evaluated cases. Furthermore, all isolates
were subjected to M-genotyping. An over-repre-
sentation of M-types M1 and M3 among severe
cases of GAS disease has been found previously,
as well as different age distribution patterns for
particular manifestations of invasive GAS disease
[14,17]. No differences were found in these param-
eters between the evaluated and non-evaluated
cases, implying that there was no reporting bias
and that the isolates evaluated were a true repre-
sentation of all cases of invasive GAS disease.
The present study found that a large number of
the isolates evaluated did not meet the criteria for
invasive GAS disease. In particular, the submis-
sion of isolates from RPHLs that did not meet the
criteria for invasive GAS disease increased after
May 1994. It is impossible to determine whether
these isolates were truly suspected to be associ-
ated with invasive disease, or whether there were
other reasons for this increased rate of submis-
sion. Of 1312 cases evaluated, 432 (33%) proved
to be non-invasive, thereby allowing the specific-
ity of defining invasiveness solely on microbiolo-
Table 3. Comparison of invasiveness of group A strepto-
coccal isolates defined on microbiological criteria alone
with invasiveness defined on the basis of both clinical and
microbiological criteria
Clinically and microbiologically
defined (no. of isolates)
Invasive Non-invasive Total
Microbiologically defined
Invasive 582 3 585
Non-invasive ⁄unknown 298 429 727
Total 880 432 1312
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gical criteria to be assessed. This approach was
found to be > 99% specific; that is, isolation of
group A streptococci from a normally sterile site
implied invasive disease. However, not all iso-
lates that gave rise to an invasive syndrome were
obtained from a sterile site, thereby limiting the
sensitivity of this approach. Among all cases of
invasive GAS disease, only 66% were detected on
microbiological criteria alone, with the remaining
isolates being identified only following the inclu-
sion of clinical data. This phenomenon must be
taken into account when comparing incidence
figures from studies based only on microbiologi-
cal criteria with those from studies that also
include clinical evaluation. Indeed, a significant
proportion of the reported geographical variation
in the incidence and serotype distribution of
invasive GAS disease may be attributable to
differences in the selection of cases, which are
intrinsic to different surveillance systems.
Clinical evaluation adds significantly to the costs
of a surveillance system. Therefore, GAS surveil-
lance based on microbiological criteria alone was
continued after December 1996 [19], but was
corrected to take account of the limited sensitivity
of this approach, which was quantifiable after both
clinical and microbiological evaluation for almost
5 years. An estimate of the true rate of invasive
GAS disease in a country should be based on an
active, population-based surveillance system
which includes both microbiological and clinical
data. However, invasiveness defined on the basis
ofmicrobiological criteria alone is very specific and
can be used for monitoring incidence trends.
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